• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

安全性研究中疫苗接种后的剂量部位反应及相关发现。

Dose site reactions and related findings after vaccine administration in safety studies.

作者信息

Baldrick Paul

机构信息

Regulatory Strategy, Covance Laboratories Ltd, England, UK.

出版信息

J Appl Toxicol. 2016 Aug;36(8):980-90. doi: 10.1002/jat.3314. Epub 2016 Mar 10.

DOI:10.1002/jat.3314
PMID:26968331
Abstract

Potential new human vaccines undergo toxicology testing to evaluate local reactogenicity and systemic toxicity. A review of 30 recently published and in-house repeat dose toxicity studies with a variety of vaccines was performed. Species tested were generally rat or rabbit, usually by intramuscular (although occasionally subcutaneous) injection. Results showed no unexpected findings indicating vaccine toxicity, but classic signs of enhanced acute and/or chronic inflammation at the dose site compared with that seen in injected control animals, often accompanied by changes in draining lymph nodes and the spleen (lymphoid hyperplasia and/or increased weight). Other associated signs of a response to vaccine dosing were altered clinical pathology parameters (commonly raised blood neutrophil count and altered globulin level). No obvious difference in dose site or systemic reaction was seen across vaccine, species or the dose route used. A non-dose recovery period of 2 to 4 weeks was sufficient to show evidence of reversibility of dose site effects. Injection site, lymphoid tissue and clinical pathological changes can be interpreted as related to an expected reaction after vaccine dosing, with generation of an immune response largely as a result of the presence of adjuvant, although direct vaccine antigen involvement was also occasionally demonstrated by the presence of a slightly increased inflammatory response seen over adjuvant treatment only. Overall, the need for toxicity testing of vaccines is in line with current regulatory guideline requirements and has proven to be a valuable part of the safety evaluation process prior to human use. Copyright © 2016 John Wiley & Sons, Ltd.

摘要

潜在的新型人类疫苗需进行毒理学测试,以评估局部反应原性和全身毒性。我们对30项最近发表的以及内部开展的针对多种疫苗的重复剂量毒性研究进行了综述。受试物种一般为大鼠或兔子,通常采用肌肉注射(尽管偶尔也采用皮下注射)。结果显示,未发现表明疫苗毒性的意外结果,但与注射对照动物相比,给药部位出现了急性和/或慢性炎症增强的典型迹象,常伴有引流淋巴结和脾脏的变化(淋巴样增生和/或重量增加)。疫苗给药反应的其他相关迹象为临床病理学参数改变(常见的是血液中性粒细胞计数升高和球蛋白水平改变)。在所使用的疫苗、物种或给药途径方面,未观察到给药部位或全身反应有明显差异。2至4周的无剂量恢复期足以显示给药部位效应可逆性的证据。注射部位、淋巴组织和临床病理变化可解释为与疫苗给药后的预期反应相关,免疫反应的产生很大程度上是由于佐剂的存在,尽管仅在佐剂处理时观察到的轻微炎症反应增加偶尔也表明直接涉及疫苗抗原。总体而言,疫苗进行毒性测试符合当前的监管指南要求,并且已证明是人类使用前安全性评估过程中的一个重要部分。版权所有© 2016约翰威立父子有限公司。

相似文献

1
Dose site reactions and related findings after vaccine administration in safety studies.安全性研究中疫苗接种后的剂量部位反应及相关发现。
J Appl Toxicol. 2016 Aug;36(8):980-90. doi: 10.1002/jat.3314. Epub 2016 Mar 10.
2
Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant.含铝佐剂重组化脓性链球菌疫苗的临床前安全性研究。
J Appl Toxicol. 2017 Feb;37(2):222-230. doi: 10.1002/jat.3349. Epub 2016 May 30.
3
Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.在生命的第二年,评估九种抗原含量降低和/或无佐剂的候选百白破疫苗作为第四剂(加强)剂量的效果。
Vaccine. 2006 Jul 7;24(27-28):5627-36. doi: 10.1016/j.vaccine.2006.04.019. Epub 2006 May 2.
4
Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies.在兔疫苗非临床安全性研究中评估C反应蛋白作为炎症生物标志物的作用。
J Pharmacol Toxicol Methods. 2013 Nov-Dec;68(3):367-73. doi: 10.1016/j.vascn.2013.04.003. Epub 2013 Apr 23.
5
Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.Pollinex Quattro豚草疫苗:一种新型单磷酰脂质A(MPL)佐剂变应原疫苗治疗豚草花粉过敏的安全性评价
J Appl Toxicol. 2007 Jul-Aug;27(4):399-409. doi: 10.1002/jat.1223.
6
Study designs for the nonclinical safety testing of new vaccine products.新型疫苗产品非临床安全性试验的研究设计。
J Pharmacol Toxicol Methods. 2012 Jul;66(1):1-7. doi: 10.1016/j.vascn.2012.04.003. Epub 2012 Apr 24.
7
Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity.在 Sprague Dawley 大鼠中重复肌内注射 CIMAvax-EGF 疫苗可引起局部和全身毒性。
Vaccine. 2012 May 9;30(22):3329-38. doi: 10.1016/j.vaccine.2012.01.092. Epub 2012 Mar 17.
8
Review of L-tyrosine confirming its safe human use as an adjuvant.L-酪氨酸作为佐剂在人体安全使用的综述。
J Appl Toxicol. 2002 Sep-Oct;22(5):333-44. doi: 10.1002/jat.869.
9
Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats.人乳头瘤病毒16/18疫苗在兔和大鼠体内单次及重复肌肉注射的非临床安全性评估
J Appl Toxicol. 2015 Dec;35(12):1577-85. doi: 10.1002/jat.3131. Epub 2015 Mar 6.
10
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.佐剂和抗原在细胞培养 H5N1 流感疫苗中的剂量范围:1/2 期临床试验的安全性和免疫原性。
Vaccine. 2010 Jan 8;28(3):840-8. doi: 10.1016/j.vaccine.2009.10.019. Epub 2009 Oct 14.

引用本文的文献

1
A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines.作为佐剂疫苗非临床安全性评估的一种可行选择的平台方法。
NPJ Vaccines. 2025 Aug 13;10(1):192. doi: 10.1038/s41541-025-01245-3.
2
Efficacy and safety of a novel multivalent mRNA vaccine against SARS-CoV-2 in experimental animals.一种新型多价抗SARS-CoV-2 mRNA疫苗在实验动物中的有效性和安全性。
Sci Rep. 2025 Jul 1;15(1):21831. doi: 10.1038/s41598-025-07661-8.
3
Clinical Pathology Evaluation in Pet Rabbits Vaccinated Against Rabbit Hemorrhagic Disease Virus 2 (RHDV2).
接种兔出血症病毒2型(RHDV2)疫苗的宠物兔的临床病理学评估
Animals (Basel). 2024 Oct 19;14(20):3029. doi: 10.3390/ani14203029.
4
The need for development of other enterovirus vaccines in addition to EV-A71 vaccine.除了肠道病毒A71疫苗外,还需要研发其他肠道病毒疫苗。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2340854. doi: 10.1080/21645515.2024.2340854. Epub 2024 Apr 23.
5
Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally.经皮内免疫的二价灭活 EV71-CA16 疫苗在小鼠中的临床前安全性评价。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2209472. doi: 10.1080/21645515.2023.2209472.
6
Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models.DTacP-sIPV-Hib 联合疫苗在动物模型中的安全性和免疫原性。
Hum Vaccin Immunother. 2022 Dec 30;18(7):2160158. doi: 10.1080/21645515.2022.2160158. Epub 2022 Dec 28.
7
Development of COVID-19 therapies: Nonclinical testing considerations.COVID-19 疗法的研发:非临床测试考量。
Regul Toxicol Pharmacol. 2022 Jul;132:105189. doi: 10.1016/j.yrtph.2022.105189. Epub 2022 May 21.
8
Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs.一种rVSV-ΔG-SARS-CoV-2-S疫苗在小鼠、仓鼠、兔子和猪身上的初步非临床安全性和免疫原性
Arch Toxicol. 2022 Mar;96(3):859-875. doi: 10.1007/s00204-021-03214-w. Epub 2022 Jan 15.
9
Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19.在大鼠中接触 AS03 佐剂的重组植物来源的病毒样颗粒疫苗候选物后,对雌性生育力或后代的围产期和产后发育无影响。
Reprod Toxicol. 2022 Jan;107:69-80. doi: 10.1016/j.reprotox.2021.11.006. Epub 2021 Nov 24.
10
Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations.评价 AV7909 炭疽疫苗在 SD 大鼠肌肉注射 3 次后的毒性。
Int J Toxicol. 2021 Oct;40(5):442-452. doi: 10.1177/10915818211031239. Epub 2021 Jul 19.